Tetanus

New Data Suggest UPLIZNA® (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) Did Not Increase the Risk of COVID-19 Infection or Reduce Antibody Levels From Childhood Vaccines

Retrieved on: 
Thursday, February 23, 2023
Health, Other Health, COVID-19, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Tetanus, Safety, Civil service commission, Learning, Doctor of Philosophy, Patient, University, Research, Neuroscience, Treatment, Neurology, Risk, Deep vein thrombosis, Great America Committee, NMOSD, Mumps, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MAS, Multiple sclerosis, Infection, History, Rubella, Pulmonary embolism, Varicella zoster virus, Fatality, Measles, European Commission, Incidence, Neuromyelitis optica spectrum disorder, Food, Vaccine, COVID, Pharmaceutical industry

These data suggest UPLIZNA does not increase susceptibility to COVID infection or deplete childhood vaccine-generated antibodies.

Key Points: 
  • These data suggest UPLIZNA does not increase susceptibility to COVID infection or deplete childhood vaccine-generated antibodies.
  • In total, the analysis found a low incidence rate of infections (0.024 events per patient year) among UPLIZNA-treated patients.
  • Of the 10 patients with known outcomes, six were reported as “recovered/resolved,” two as not recovered/resolved and two patients died.
  • “The results of these analyses provide further support that UPLIZNA is an effective long-term treatment for NMOSD with a favorable safety profile.”

Americaneagle.com Announces Launch of Customer Portal and Updated Website for At-Home Antibody Test Panel Company, ImmunoProfile

Retrieved on: 
Thursday, February 2, 2023
Cold medicine, Chickenpox, Infection, World Health Organization, API, Patient, Mumps, Health, Measles, Risk, Hepatitis A, Diphtheria, WHO, Rubella, Partnership, Tetanus, Social media, Online shopping, Vaccine

First, Americaneagle.com designed the website with a secure and confidential customer portal for purchasing ImmunoProfile's products.

Key Points: 
  • First, Americaneagle.com designed the website with a secure and confidential customer portal for purchasing ImmunoProfile's products.
  • Second, the customer portal manages multiple logistical processes including those required for medical diagnostic testing in a CLIA/CAP-certified testing laboratory and the secure delivery of the customer's confidential test results.
  • ImmunoProfile offers the first-ever at-home collection Serology Antibody Test Panel for 11 common infectious diseases.
  • The test is engineered to determine personal levels of antibody protection against multiple infectious diseases in one test panel.

Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023

Retrieved on: 
Monday, January 16, 2023
Hospital, World Health Organization, Foot, Severe acute respiratory syndrome coronavirus 2, Pediatrics, SCB-2019, Commercial, COVID-19 vaccine, Oral and maxillofacial pathology, EUA, Death, Vaccination, Environment, Health, Research, Whooping cough, EMA, GMP, Development, WHO, Diphtheria, CAS-1, European Medicines Agency, RSV, Co-promotion, G&A, COVID-19, CpG, Safety, Respiratory syncytial virus, Vaccine, RMB, Omicron, Tetanus, EV71, DPT vaccine, Immunity, Pharmaceutical industry, Fine chemical, Risk management, Hand, Clover

SHANGHAI, China, Jan. 15, 2023 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today provided updates on the commercialization of SCB-2019 (CpG 1018/Alum) in China and strategic priorities in 2023.

Key Points: 
  • Commercial Launch Expected to Begin in Q1 2023: Clover has started commercial launch preparation activities in multiple key provinces and municipalities, based on Clover’s evaluation of market dynamics (including factors such as strategic fit, population size and competitive environment).
  • To date, Clover has received robust interest and demand based on the premium product profile of SCB-2019 and expects the commercial launch in these strategically prioritized areas to begin in Q1 2023.
  • At Least One In-Licensing Deal in H1 2023: At least one mid- to late-stage vaccine in-licensing deal announcement is expected in H1 2023.
  • SCB-2019: Concurrent with its commercial launch in China, Clover plans to conduct real-world effectiveness studies, with data potentially available in H2 2023.

2022 World Market for Vaccines: The Market is Valued at $202.6 Billion up from $34.1 Billion in 2017 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 7, 2022
Infectious Diseases, Pharmaceutical, Health, COVID-19, Vaccination, Vaccine, Diphtheria, Public health, Infection, Society, Population growth, Death, Disease, Cowpox, Haemophilus influenzae, Rubella, Quality of life, COVID-19, Smallpox, Human, Growth, WHO, Tetanus, Statistics, Forecasting, Whooping cough, Vaccine-preventable diseases, Pharmaceutical industry

However, mitigating against growth will be continuing concerns about vaccine safety, availability in developing countries and refusal to immunize.

Key Points: 
  • However, mitigating against growth will be continuing concerns about vaccine safety, availability in developing countries and refusal to immunize.
  • The report contains market forecasts, company market share and expert market estimates for vaccine categories.
  • The report also looks at trends in the market for human vaccines used to prevent various types of disease.
  • It also covers the COVID-19 vaccine market landscape and estimated market opportunity during the forecast period.

Global Toxoid Vaccine Market Report 2022 to 2028: Featuring Astellas Pharma, Bharat Biotech, Novartis and Pfizer Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, December 5, 2022
Health, Pharmaceutical, TD, Ageing, Diphtheria, Whooping cough, UIP, Prevalence, Hospital, Death, Disease, National Health Mission, TT, DT, World Health Organization, Government, ClinicalTrials.gov, Tetanus, Vaccine, Growth, Immunity, WHO, TDAP, DPT vaccine, Marketing

The global toxoid vaccine market is segmented based on disease, composition, form, and end-user.

Key Points: 
  • The global toxoid vaccine market is segmented based on disease, composition, form, and end-user.
  • Geographically, the global toxoid vaccine market is segmented into North America, Europe, Asia Pacific, and the Rest of the World.
  • The North American region is expected to hold a prominent market share in the global toxoid vaccine market.
  • Insights about market determinants that are stimulating the global toxoid vaccine market.

Travel Vaccine Global Market Report 2022: Stringent Advisories and Regulations by Health Authorities to Aid Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 1, 2022
Other Travel, Pharmaceutical, Health, Travel, Sissel v. United States Department of Health & Human Services, COVID-19, Growth, Rotavirus, Typhoid fever, International Certificate of Vaccination or Prophylaxis, Human services, National Health Service, Health, Vaccine, Infection, Tetanus, Hepatitis B, Antibody, Hepatitis A, Fever Dream, Shingles, Tourism, Yellow fever, Travel, Cholera, Meningitis, Diphtheria, Disease, Spiritualism, Vaccination, Rubella, Mumps, Measles, Polio, Composition, Chickenpox, NHS, DPT, Rabies

The global travel vaccine market is anticipated to grow at a steady rate in the forecast period, 2023-2027.

Key Points: 
  • The global travel vaccine market is anticipated to grow at a steady rate in the forecast period, 2023-2027.
  • The market growth can be attributed to the rising incidences of flu and rapid growth in the travel and tourism sector.
  • Travel vaccines, also known as travel immunizations, are vaccine shots that protect travelers from serious illnesses.
  • Increasing regulations for safe traveling are supporting the normalization of travel vaccines among travelers, which is expected to boost the market growth.

Double Rainbow Announces World’s First Commercial-Scale Biosynthetic Gastrodin, a Natural Analgesic with a Range of Therapeutic Applications

Retrieved on: 
Monday, November 28, 2022
Hypoesthesia, Mental health, Dizziness, Herbal medicine, Epilepsy, Environment, Tetanus, Public sector, Genomics, Analgesic, Biotechnology, Chronic pain, Patient, Double Rainbow, Headache, Metabolomics, Medicine, Convulsion, Paralysis, Opioid, Health, Therapy, Synthetic biology, Rheumatism, Pharmaceutical industry, Fine chemical, Gastrodia

In 1984, the Chinese regulatory authority approved Gastrodin for pharmaceutical use as a non-addictive sedative and analgesic.

Key Points: 
  • In 1984, the Chinese regulatory authority approved Gastrodin for pharmaceutical use as a non-addictive sedative and analgesic.
  • We are unlocking the full therapeutic potential of natural products, such as Gastrodin, by creating sustainable, high-quality production methods for rare ingredients, said Jing-Ke Weng, Co-Founder of DoubleRainbow Biosciences.
  • Gastrodin is a powerful natural analgesic, with a rich history of use in traditional medicine cultures.
  • In addition to Gastrodin, Double Rainbow is advancing a rich pipeline of biosynthetic compounds, with the goal to deliver more than a dozen commercial-scale medicinal products by 2025.

Pediatric Vaccines Global Markets Report 2022: Impacts of COVID-19, Market Revenue Data for 2020 and 2021, Estimates for 2022, and CAGR Projections through 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 24, 2022
COVID-19, Consumer, Health, Pharmaceutical, Children, BCG, Investment, Incidence, Pfizer–BioNTech COVID-19 vaccine, CoronaVac, China National Pharmaceutical Group, Chickenpox, Pfizer, Vaccine, WHO, Dros, GlaxoSmithKline, Abbott Laboratories, Whooping cough, Mumps, Gavi, Merck & Co., Hepatitis, Measles, AstraZeneca, Global health, Child, Diphtheria, Mortality, Bharat Biotech, Vaccine-preventable diseases, Organization, COVID-19, Tetanus, UNICEF, Pharmaceutical industry

This report highlights the current and future market potential of pediatric vaccines and a detailed analysis of the market's drivers, challenges and opportunities.

Key Points: 
  • This report highlights the current and future market potential of pediatric vaccines and a detailed analysis of the market's drivers, challenges and opportunities.
  • The report also covers market projections through 2027 and estimates market shares for key players, as well as pediatric vaccines by type and by application.
  • The report also discusses the impact of the COVID-19 pandemic on this market.
  • Vaccines are one of the most significant advances in global health and are the most cost-effective strategy to reduce child mortality.

Protect Me With 3+ contest submissions now open for NJ middle, high school students to raise vaccine awareness

Retrieved on: 
Thursday, November 3, 2022
Vaccine, Awareness, State epidemiologist (Sweden), Protect Me, Student, Visa, New Jersey Department of Health, Infection, PMCH, COVID-19, CEO, State, Tetanus, Vaccine-preventable diseases, Digital, BSN, Neisseria meningitidis, Centers for Disease Control and Prevention, DOH, Creativity, Mother, DPT vaccine, Health status of Asian Americans, Health education, Center, Health, Child, Partnership, MA, Create, Assistant commissioner, Hand, Family, HPV, Poster, Diphtheria

NEWARK, N.J., Nov. 3, 2022 /PRNewswire-PRWeb/ -- Calling all New Jersey middle and high school students! This year's Protect Me With 3+ vaccine awareness contest is now open for poster and video submissions through Jan. 20, 2023.

Key Points: 
  • Poster, video contest encourages students to get creative to protect, educate NJ communities
    NEWARK, N.J., Nov. 3, 2022 /PRNewswire-PRWeb/ -- Calling all New Jersey middle and high school students!
  • This year's Protect Me With 3+ vaccine awareness contest is now open for poster and video submissions through Jan. 20, 2023.
  • contest seeks to motivate students to create posters and videos illustrating the importance of getting vaccinated to achieve the highest level of community protection.
  • The goal is to use the power of students' creativity to raise awareness of the importance of vaccines in protecting New Jerseyans' health and encourage more students and teachers to participate statewide.

Global Infectious Diseases Partnering Deal Trends, Players and Financials Analysis Report 2015-2022 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 25, 2022
Health, Infectious Diseases, Campylobacter jejuni, MRSA, SEC, Directory, Review, Yellow fever, Salmonella, Global Infectious Disease Epidemiology Network, Chapter Three, Chapter One, Respiratory syncytial virus, Orientation, Contract, RSV, Chapter Five, Research, Anthrax, FIV, Methicillin-resistant Staphylococcus aureus, Escherichia coli, Technology, Haemophilus influenzae, Common cold, HIV, Chapter Six, Foot, Chapter Two, Herpes simplex, Dengue fever, A-Z, Tetanus, Mycobacterium avium complex, Streptococcus, Clostridium difficile, Hepatitis A, Lyme disease, Chapter Four, Pseudomonas aeruginosa, African trypanosomiasis, Hyperlink, Helicobacter pylori, TB, Vaccine, Pharmaceutical industry, Haemophilus, West Nile virus, Infection, Tuberculosis, H1N1, Zika fever, Sepsis, Cytomegalovirus, Diphtheria, Malaria

The "Global Infectious Diseases Partnering 2015-2022: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Infectious Diseases Partnering 2015-2022: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
  • The Global Infectious Diseases Partnering 2015-2022 report provides comprehensive access to available deals and contract documents for over 2,900 infectious diseases deals.
  • The report takes readers through the comprehensive Infectious Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Infectious Diseases deals.
  • Chapter 6 provides a comprehensive directory of all Infectious Diseases partnering deals by specific Infectious Diseases target announced since 2015.